NasdaqCM - Delayed Quote USD

Cyclacel Pharmaceuticals, Inc. (CYCC)

1.7900 +0.0400 (+2.29%)
At close: 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
420.0000
420.0000
--
--
--
Operating Expense
25,873.0000
25,873.0000
27,656.0000
22,389.0000
10,636.0000
Operating Income
-25,453.0000
-25,453.0000
-27,656.0000
-22,389.0000
-10,636.0000
Net Non Operating Interest Income Expense
266.0000
266.0000
210.0000
16.0000
42.0000
Other Income Expense
-364.0000
-364.0000
1,531.0000
188.0000
913.0000
Pretax Income
-25,551.0000
-25,551.0000
-25,915.0000
-22,185.0000
-9,681.0000
Tax Provision
-2,996.0000
-2,996.0000
-4,717.0000
-3,728.0000
-1,236.0000
Net Income Common Stockholders
-22,756.0000
-22,756.0000
-21,399.0000
-18,658.0000
-12,421.0000
Diluted NI Available to Com Stockholders
-22,756.0000
-22,756.0000
-21,399.0000
-18,658.0000
-12,421.0000
Basic EPS
-26.75
-26.75
-28.70
-32.10
-51.30
Diluted EPS
-26.75
-26.75
-28.70
-32.10
-51.30
Basic Average Shares
850.8150
850.8150
657.6200
595.0780
242.2250
Diluted Average Shares
850.8150
850.8150
657.6200
595.0780
242.2250
Total Operating Income as Reported
-25,453.0000
-25,453.0000
-27,656.0000
-22,389.0000
-10,636.0000
Total Expenses
25,873.0000
25,873.0000
27,656.0000
22,389.0000
10,636.0000
Net Income from Continuing & Discontinued Operation
-22,555.0000
-22,555.0000
-21,198.0000
-18,457.0000
-8,445.0000
Normalized Income
-22,189.5439
-22,189.5439
-21,388.5898
-18,493.6062
-8,464.1912
Interest Income
266.0000
266.0000
210.0000
16.0000
42.0000
Net Interest Income
266.0000
266.0000
210.0000
16.0000
42.0000
EBIT
-25,453.0000
-25,453.0000
-27,656.0000
-22,389.0000
-10,636.0000
EBITDA
-25,422.0000
-25,422.0000
-27,624.0000
-22,346.0000
-10,616.0000
Reconciled Depreciation
31.0000
31.0000
32.0000
43.0000
20.0000
Net Income from Continuing Operation Net Minority Interest
-22,555.0000
-22,555.0000
-21,198.0000
-18,457.0000
-8,445.0000
Total Unusual Items Excluding Goodwill
-414.0000
-414.0000
233.0000
44.0000
22.0000
Total Unusual Items
-414.0000
-414.0000
233.0000
44.0000
22.0000
Normalized EBITDA
-25,008.0000
-25,008.0000
-27,857.0000
-22,390.0000
-10,638.0000
Tax Rate for Calcs
0.0001
0.0001
0.0002
0.0002
0.0001
Tax Effect of Unusual Items
-48.5439
-48.5439
42.4102
7.3938
2.8088
12/31/2020 - 3/16/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CMMB Chemomab Therapeutics Ltd.
0.6700
+1.53%
 
TRVI Trevi Therapeutics, Inc.
2.8500
-3.06%
 
FNCH Finch Therapeutics Group, Inc.
2.7888
+22.85%
 
PRTG Portage Biotech Inc.
0.2426
-19.46%
 
COEP Coeptis Therapeutics Holdings, Inc.
0.3350
-3.18%
 
SABS SAB Biotherapeutics, Inc.
4.3600
-1.13%
 
TENX Tenax Therapeutics, Inc.
3.5000
-1.41%
 
DRMA Dermata Therapeutics, Inc.
0.3397
+0.32%
 
IMNN Imunon, Inc.
1.3300
+4.72%
 
GNFT Genfit S.A.
3.4449
+0.43%